Skip Navigation

Skip Navigation

Issue No. 5  | February 07, 2013
View HTML version

Subscribe to the AIDSinfo At-a-Glance
e-newsletter to receive regular updates on the latest in HIV/AIDS treatment, prevention, and research.

Globe of the earth

February 7 is National Black HIV/AIDS Awareness Day

AIDSinfo joins individuals and organizations across the nation in observing National Black HIV/AIDS Awareness Day. The awareness day is set aside each year to acknowledge the disproportionate burden of HIV/AIDS in the African-American community. In 2009, according to CDC, African Americans represented 14% of the U.S. population but accounted for 44% of all new HIV infections.

To learn more about HIV/AIDS and African Americans, please explore our National Black HIV/AIDS Awareness Day webpage [en español].


Explore the Updated AIDSinfo and infoSIDA Mobile Sites

Check out our updated AIDSinfo and infoSIDA mobile sites!
 
Updates include the following:

  • New design that evokes the look and feel of an app
  • Reorganized content to match the display on the redesigned AIDSinfo and infoSIDA websites
  • Improved navigation to make information easier to access
  • Addition of the news section and e-newsletter sign-up page
  • Improved access to Facebook and Twitter links
  • Addition of a home page image slideshow to highlight new and updated website content
  • Improved search engine optimization (SEO) to make it easier for Google and other search engines to index content on the sites

We will continue to update our mobile sites to meet the increasing demand for on-the-go access to HIV/AIDS-related information.
 
Please send your comments on the mobile sites to ContactUs@aidsinfo.nih.gov.


FDA Updates Darunavir Tablet and Oral Suspension Labeling with Pediatric Dosing Information

“On February 1, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to include once daily dosing in treatment-naïve subjects 3 to less than 18 years of age and once daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.”

The updated labeling will be available at the FDA website.

More information is available:


Twitter - Stay connected FaceBook - Stay connected
ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228